Sun Pharmaceutical Industries Ltd
|
|
- Sheila Pitts
- 6 years ago
- Views:
Transcription
1 1 Sun Pharmaceutical Industries Ltd Event Update 23 rd March, 2018
2 Mar-15 Sep-15 Mar-16 Sep-16 Mar-17 Sep-17 Mar-18 India Equity Institutional Research II Event Update II 23 rd March, CMP INR 508 Target INR 633 Potential Upside 25% Market Cap (INR Mn) 1,210,938 Recommendation BUY Sector Pharma USFDA approval of ILUMYA (tildrakizumab) for the treatment of moderate-to-severe plaque psoriasis Sunpharma has received USFDA approval for tildrakizumab which was originally developed by US based company Merck and later in 2014, Sunpharma acquired the worldwide rights from Merck for USD 80 mn. Sunpharma is entitled to pay to Merck undisclosed payments associated with regulatory (including product approval) and sales milestones as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. This was a remarkable achievement for SUN and a first step towards development of its innovative pipeline Following are the key highlights: o Psoriasis is an autoimmune disorder which has a market size of USD 6 bn in the US and is growing in single digit. There are various treatment options available in the market and but none of them offers a cure. Sunpharma s molecule will be ninth biologic to be approved on US markets. o For US region Sunpharma is entitled to pay to Merck undisclosed payments associated with regulatory (including product approval) and sales milestones as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. o For European region Sunpharma had entered into entered into a licensing agreement with Almirall for development and commercialisation of the drug. Almirall will pay Sun Pharma an initial upfront payment of US $50 million and Sun Pharma will be eligible to receive development and regulatory milestone payments along with sales milestone payments and royalties. o o We expect the peak sales of Tildrakizumab to be around USD 300 mn in 2022 and we assume the market share for Tildra to be 9%. As the psoriasis market is already crowded we believe that the company has to sell the drugs at a lower price than its competitors in order to gain a fair market share. The clinical studies of Tildra vs is asfollows: Efficacy Primary Endpoint at Week 12 in Tildrakizumab (ILUMYA) resurface 1 Study resurface 2 Study (NCT ) (NCT ) ILUMYA ILUMYA 100 mg 100 mg n=309 n=154 n=307 n=156 PGA of "clear" (0) or "minimal" (1) 179 (58%) 11 (7%) 168 (55%) 7 (4%) PASI (64%) 9 (6%) 188 (61%) 9 (6%) PASI 90 35% 3% 39% 1% PASI % 1% 12% 0% Efficacy Primary Endpoint at Week 12 in Secukinumab () IGA of "clear" or utmost clear (N=245) n (%) (N=327) n (%) 300 mg 150 mg (N=245) (N=248) (N=245) (N=248) 160 (65%) 6 (2%) 174 (71%) 6 (2%) PASI 75 response 200 (82%) 11 (4%) 125 (51%) 11 (4%) PASI 90 (52 Weeks) 76.20% 60.60% - - PASI % 35.80% - - The Psoriasis Area and Severity Index (PASI) is a validated measure used frequently in clinical trials for psoriasis treatments to determine the severity of psoriasis. In the above study, PASI 75 score represents a 75% improvement from baseline in PASI score and is considered to be a clinically meaningful endpoint. For Tildra the PASI 75 score is 64% as compared to the placebo (benchmark studies) which is at 6%. But when we compare these studies from the competitor, then have a better efficcacy results. The PASI score of in PASI 75 is 65% vs 64% in tildrakizumab. But at higher scores of PASI 90 stands at superior level of 76% vs 35% in tildrakizumab. Overall, we believe that the Tildrakizumab has a mediocre level efficacy than its competitor which will make a tough and competitive environment for the drug. MARKET DATA Shares outs (Mn) 2399 EquityCap (INR Mn) 2399 Mkt Cap (INR Mn) Wk H/L (INR) 710/433 Volume Avg (3m K) Face Value (INR) 1 Bloomberg Code SUNP IN SENSEX NIFTY Sunpharma Industries Sensex SHARE HOLDING PATTERN (%) Particulars Dec 17 Sep 17 Jun 17 Promoters FIIs DIIs Others Total
3 Competitive landscape for Tildrakizumab 3 Brand Name API Company Class of drug Therapy class Sales 2016 (USD mn) Approval Date secukinumab Novartis interleukin (IL)-17A mab 1,100 Jan-15 Enbrel etarnacept Amgen anti-tnf Immune Suppressant 8,875 Nov-98 Stelara Ustekinumab J&J interleukin 12 mab 3,232 Sep-09 Humira adalimumab Abbvie anti-tnf mab 16,100 Dec-02 Taltz ixekizumab Eli Lilly interleukin (IL)-17A mab 61 Mar-16 Market share of drugs in 2017 Source: Abbvie investor presentation, Market model of Tildrakizumab Total Population US Psoriasis patients (000) 7,500 7,500 7,500 7,665 7,834 (%) Increase 0.0% 2.2% 2.2% Moderate-to-severe (%) 20% 20% 20% 20% 20% Eligible Pts (000) 1,500 1,500 1,500 1,533 1,567 US Penetration (%) 3% 5% 8% 9% 10% Patients on Tildra (000) Average cost of therapy in USD 21,000 21,315 21,635 21,959 22,398 (%) Price increase 1.50% 1.50% 1.50% 2% Total US sales (USD mn) Royalties to Merck in USD mn 5% Total sales in USD mn Total US sales in INR mn 5,683 9,613 15,612 18,219 21,103 EU Psoriasis patients (000) 14,000 14,000 14,308 14,623 (%) Increase 0.0% 2.2% 2.2% Moderate-to-severe (%) 20% 20% 20% 20% Eligible Pts (000) 2,800 2,800 2,862 2,925 US Penetration (%) 5% 7% 9% 11% Patients on Tildra (000) Average cost of therapy in USD 21,000 21,315 21,635 21,959 (%) Price increase 1.50% 1.50% 1.50% Total EU sales (USD mn) Total EU sales in INR mn 18,610 26,445 35,270 44,717 Royalties to Sunpharma (INR mn) 5% 931 1,322 1,764 2,236 (Assumption) Total sales for Sunpharma 10,544 16,934 19,983 23,339
4 Valuation: We believe that Sunpharma will start commercializing the drug post Q4 FY18 in the US markets. Due to competitive market and challenges the drug will take 2-3 years of time to reach its peak sales. We project sales of USD 95 mn in FY19 with a market share of 3%. Although the drug has lower efficacy but due to huge market size and growing patients population in psoriasis market Tildrakizumab will be able to achieve a peak sales of USD mn in This development is priced in the near term valuations. However, over the long term we believe this to be one of the key triggers in our investment thesis. We have a BUY rating on the stock with a target price of INR
5 KEY FINANCIALS Exhibit 2: Income Statement Net Sales 2,75,183 2,78,881 3,02,643 2,59,816 2,80,049 Other Operating Income 1,469 5,990 13,142 2,598 2,800 Operating Expenses 1,94,281 2,03,287 2,14,892 2,05,255 2,09,477 EBITDA 82,371 81,584 1,00,893 57,160 73,373 Depreciation 11,947 10,375 12,648 13,960 15,885 Other Income 4,508 6,583 6,232 6,792 6,929 EBIT 74,932 77,791 94,477 49,992 64,417 Interest Paid 5,790 5,232 3,998 4,203 4,893 Pre-Tax Profit 69,142 72,559 90,479 45,789 59,524 Non-Recurring Items -2,381-6, ,505 0 Pre-Tax Profit 71,523 79,410 90,479 36,284 59,524 Tax (current + deferred) 9,147 9,138 12,116 6,531 9,702 Net Profit 62,376 70,273 78,364 29,753 49,822 Minority Interests -9,363-11,126-8,819-8,827-8,836 Share of associates Net Income 52,888 59,161 69,644 20,940 41,005 Source: Company, 5 Exhibit 3 : Balance Sheet Equity Share Capital 2,071 2,407 2,399 2,399 2,399 Reserves & Surplus 2,54,309 3,27,418 3,63,997 3,89,027 4,30,939 Total Shareholders Fund 2,56,381 3,29,825 3,66,397 3,91,426 4,33,338 Minority Interest 28,512 40,853 37,909 37,909 37,909 Non- current liabilties Long Term Borrowings 27,682 32,906 31,769 33,051 34,414 Deferred Tax Liabilities 985 1,028 3,148 3,148 3,148 Other LT Liabilties & Provisions 27,187 21,055 13,418 14,655 16,014 Current Liabilities Short-term Borrowings 62,279 52,061 66,549 67,031 67,519 Trade Payables 31,538 35,829 43,954 44,133 44,041 Other Current Liabilities & Provisions 55,715 41,746 50,959 51,548 52,143 Total Liabilities 4,90,279 5,55,302 6,14,102 6,42,901 6,88,526 Non- current Assets Fixed Assets 1,10,202 1,24,130 1,49,403 1,90,815 2,09,930 Non-Current Investments 5,989 11,161 9,610 9,706 9,803 Goodwill 37,010 56,347 55,362 55,362 55,362 Other Non-Current Assets 45,860 64,252 70,190 70,464 70,742 Current assets Current Investments 21,174 7,138 2,309 2,424 2,545 Trade Receivables 53,123 67,757 72,026 65,488 69,053 Inventories 56,680 64,225 68,328 68,406 67,672 Cash & Bank Balances 1,09,980 80,751 86,628 78,053 99,191 Short Term Loans & Advances 21,933 10,716 10,191 10,395 10,603 Other Current Assets 28,329 68,826 90,055 91,789 93,624 Total Assets 4,90,279 5,55,303 6,14,102 6,42,901 6,88,526 Source: Company,
6 Exhibit 4: Cash flow statement 6 PBT 64,029 65,707 90,479 36,284 59,524 Depreciation 11,947 10,375 12,648 13,960 15,885 Change in Working Capital 1,796 2,468-4,092 6,254-3,291 Other items Cash flow from operations 56,158 66,859 70,823 54,169 67,308 Proceeds from sale of fixed assets -23,419-34,035-36, Payments for purchase of property, plant and equipment Other Investing Activities Cash flow from investing -28,657-43,716-42,216-55,583-35,218 Proceeds from borrowings 79,184 82,945 53,640 1,765 1,850 Repayment of borrowings -96,645-90,765-45, Finance costs (includes borrowing costs capitalised) Dividend paid -3,105-7,217-2,399-4,723-7,909 Others 12, , Cash flow from financing -11,865-18,885-22,854-6,958-10,952 Net increase in cash and cash equivalents 15,635 4,258 5,753-8,371 21,138 Opening Cash Balance 43,587 72,856 80,317 86,424 78,053 Effect of exchange differences on restatement of foreign currency cash and cash equivalents 1,208 4, Pursuant to the Scheme of Amalgamation 12, Closing Cash Balance 72,856 81,338 86,424 78,053 99,191 Source: Company, Exhibit 5: Ratio Analysis EPS CEPS BVPS DPS Valuation (x) P/E P/BV EV/EBITDA Return ratio (%) EBIDTA Margin 28.9% 29.3% 33.3% 22.0% 26.2% PAT Margin 19.9% 20.3% 25.9% 11.5% 17.8% RoE 24.9% 19.3% 22.5% 7.9% 12.1% RoCE 19.9% 16.7% 19.5% 9.0% 11.0% Leverage Ratios (x) Long Term D/E Net Debt/Equity Debt/EBITDA Interest Coverage Current ratio Growth Ratios (%) Income growth 72% 1% 9% -14% 8% EBITDA growth 10.7% 2.4% 23.7% -43.3% 28.4% PAT growth 39% 3% 39% -62% 67% Turnover Ratios Asset Turnover (x) Inventory Days Debtors Days Source: Company,
7 7. Date CMP (INR) TP (INR) Recommendation 22-Mar BUY 15-Feb ACCUMULATE 15-Nov BUY 14-Aug BUY 15-Feb BUY 11-Nov BUY 16-Aug BUY 01-Jun BUY 15-Feb BUY 12-Aug ACCUMULATE 21-Jul ACCUMULATE 8-Jul ACCUMULATE 30-May HOLD 9-April HOLD 16-Feb ACCUMULATE Rating Legend Our Rating Upside Buy More than 15% Accumulate 5% - 15% Hold 0 5% Reduce -5% 0 Sell Less than -5% CERTIFICATION: We, Vaibhav Chowdhry (B.Com, MBA), research analyst and Dhara Patwa (BBA,MBA), research associate, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Terms & Conditions and other disclosures: KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and MCX Stock Exchange Limited. KRCSSPLis a registered Research Entity vides SEBI Registration No. INH under SEBI (Research Analyst) Regulations, We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities. KRCSSPLprohibits its analysts, persons reporting to analystsand their relatives from maintaining a financial interest in the securities or derivatives of any companiesthat the analyst covers. The information and opinions in this report have been prepared by KRCSSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavor to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacityto this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary ortrading strategies that reflect opinions that are contrary to the opinions expressed herein,.in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potentialconflicts of interest. Associates (Group Companies) of KRCSSPL might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services. KRCSSPLor its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject companyin the past twelve months KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts have any material conflict of interest at the time of publication of this report. It is confirmed that, Vaibhav Chowdhry (B.Com, MBA), research analyst and Dhara Patwa (BBA,MBA), research associate, of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions. KRCSSPL or its associates (Group Companies) collectively or its research analyst do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publicationof the research report) in the company covered byanalyst, and has not been engaged in market making activity of the companycovered byresearch analyst. It is confirmed that, Vaibhav Chowdhry (B.Com, MBA), research analyst and Dhara Patwa (BBA,MBA), research associate, do not serve as an officer, director or employee of the companies mentioned in the report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction. Please send your feedback to research.insti@krchoksey.com Visit us at Kisan Ratilal Choksey Shares and Securities Pvt. Ltd Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai Phone: ; Fax: Corporate Office: ABHISHEK, 5th Floor, Link Road, Andheri (W), Mumbai Phone: ; Fax:
ITC Ltd. RESULT UPDATE 27th October, 2017
. RESULT UPDATE 27th October, 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update - II 27th October, 2017 CMP INR 269 Target INR 349 Potential Upside
More informationSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. RESULT UPDATE 14th August 2017 22 nd May 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j
More informationSymphony Ltd. RESULT UPDATE 31st October 2017
. RESULT UPDATE 31st October 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October 2017. CMP INR 1,465 Target INR 1,700 Potential
More informationNestle India Ltd. RESULT UPDATE
RESULT UPDATE 15th May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update Q1CY17 II 15th May, 2017 CMP INR 6819 Target INR 7075 Potential Upside
More informationColgate-Palmolive India Ltd.
RESULT UPDATE 5th February, 2018 Feb-15 Aug-15 Feb-16 Aug-16 Feb-17 Aug-17 Feb-18 India Equity Institutional Research II Result Update - Q3FY18 II 5th February, 2018 CMP INR 1,120 MARKET DATA Target INR
More informationPrabhat Dairy Ltd. RESULT UPDATE 8th June, 2018
RESULT UPDATE 8 th June, 2018 Sep-15 Jan-16 May-16 Sep-16 Jan-17 May-17 Sep-17 Jan-18 May-18 India Equity Institutional Research II Result Update - Q4FY18 II 8 th June, 2018 2 Under Expansion Mode CMP
More informationHindustan Unilever Ltd.
. RESULT UPDATE 18 th July 2017 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 Jul-17 125 105 India Equity Institutional Research II Result Update - FY18 II 18th July, 2017 CMP INR 1158 Target INR 1206 MARKET
More informationLupin Ltd. RESULT UPDATE 31 st October 2017
RESULT UPDATE 31 st October 217 22 nd May 217 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October, 217 Lupin Ltd CMP INR 127 Target
More informationBritannia Industries Ltd.
. RESULT UPDATE 30th May, 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update - Q4FY17 II 30 th May, 2017 2 Growth Path ahead CMP INR 3419 Target
More informationTata Consultancy Services
Tata Consultancy Services SALES NOTE 19 th May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Sales Note II 19th May, 2017 CMP INR 2536 Target INR 2833 Potential
More informationSuzlon Energy Ltd RESULT UPDATE 16th August, 2017
RESULT UPDATE 16 th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationBritannia Industries Ltd.
. RESULT UPDATE 9th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationBalkrishna Industries Ltd
RESULT UPDATE 3 rd August 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationLupin Ltd. RESULT UPDATE
RESULT UPDATE 3rd August 217 22 nd May 217 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 217: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-217-vote-now
More informationInfibeam Incorporation Ltd.
RESULT UPDATE 16 th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationHindustan Unilever Ltd.
. RESULT UPDATE 25th October 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update - II 25th October 2017 CMP INR 1273 Target INR 1392 Potential Upside
More informationBharat Forge Ltd RESULT UPDATE
RESULT UPDATE 9 th November 2017 Nov-14 May-15 Nov-15 May-16 Nov-16 May-17 Nov-17 160 130 100 India Equity Institutional Research II Result Update Q2FY18 II 9 th November, 2017 CMP INR 738 Target INR 840
More informationCipla Ltd. RESULT UPDATE
RESULT UPDATE 14th August 2017 22 nd May 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationBharat Forge Ltd RESULT UPDATE
RESULT UPDATE 25 th May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update - Q4FY17 II 25th May, 2017 2 Pricey valuation limits further upside CMP
More informationPersistent Systems Ltd.
RESULT UPDATE 26 th April2017 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 India Equity Institutional Research II Result Update - Q4FY17 II 26th April, 2017 2 Investment Mode Off, Return Mode On CMP INR 564 Target
More informationBharat Forge Ltd RESULT UPDATE
RESULT UPDATE 11 th August 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationTech Mahindra Ltd. RESULT UPDATE
Ltd. RESULT UPDATE 29 th May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update - Q4FY17 II 29 th May, 2017 CMP INR 374 Target INR 473 Potential
More informationSagar Cements Ltd. Management Meet Update
Management Meet Update 26th September, 2017 Sep-14 Mar-15 Sep-15 Mar-16 Sep-16 Mar-17 Sep-17 India Equity Institutional Research II Management Meet Update II 26th September, 2017 2 Robust earnings outlook!
More informationHCL Technologies Ltd.
RESULT UPDATE 12 th May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update - Q4FY17 II 12 th May, 2017 CMP INR 839 Target INR 1068 Potential Upside
More informationReliance Industries Ltd.
1. RESULT UPDATE 22 nd January, 2018 Jan-15 Jul-15 Jan-16 Jul-16 Jan-17 Jul-17 Jan-18 India Equity Institutional Research II Result Update Q3FY18 II 22nd January, 2018 CMP INR 929 Result highlights Target
More informationGodrej Consumer Products Ltd.
RESULT UPDATE 1st August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 India Equity Institutional Research II Result Update Q1FY18 II 1st August, 2017 CMP INR 1,035 Target INR 1,120 Potential
More informationPage. ICICI Bank Ltd. RESULT UPDATE 31 st July, 2017
1. RESULT UPDATE 31 st July, 2017 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 Jul-17 India Equity Institutional Research II Result Update Q1FY18 II 31st July, 2017 2 Asset quality still worrisome, slippages
More informationTech Mahindra Ltd. RESULT UPDATE
Ltd. RESULT UPDATE 1 st August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 India Equity Institutional Research II Result Update - Q1FY18 II 1st August, 2017 CMP INR 403 MARKET DATA Target INR
More informationPage. Mahanagar Gas Ltd. RESULT UPDATE 8 th August, 2018
1 RESULT UPDATE 8 th August, 2018 Jul-16 Jan-17 Jul-17 Jan-18 Jul-18 India Equity Institutional Research II Result Update Q1FY19 II 8 th August, 2018 2 CMP INR 961 Target INR 1,165 Potential Upside 21.2%
More informationPage. ICICI Bank Ltd. RESULT UPDATE 30 th October, 2017
1. RESULT UPDATE 30 th October, 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 30th October, 2017 2 Stress situation continues to improve
More informationKotak Mahindra Bank Ltd.
1. RESULT UPDATE 26 th October, 2017 Oct/14 Apr/15 Oct/15 Apr/16 Oct/16 Apr/17 Oct/17 India Equity Institutional Research II Result Update Q2FY18 II 26 th October, 2017 CMP INR 1014 Target INR 1104 Result
More informationVisaka Industries Ltd
Company Update Superior Product Mix & New Age Markets to Aid Growth New investments to aid growth: Visaka continues to give a good set of numbers. YoY EPS grew at 142% aided by a revenue growth of 1.5%
More informationUltratech Ltd. RESULT UPDATE
Ultratech Ltd. RESULT UPDATE 26th April 2017 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 India Equity Institutional Research II Result Update - Q4FY17 II 26th April, 2017 CMP INR 4238 Target INR 4266 Potential
More informationSQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E
Company Update Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E EBITDA Margins recovered by 618 bps QoQ: The company has witnessed many challenges over the year FY17 starting
More informationCummins India Ltd Bloomberg Code: KKC IN
Company Update Margins Under Pressure; Domestic Recovery Underway Half-yearly revenue was flat; margins were under pressure: Cummins India revenue, EBITDA and PAT for H1FY17 reached to Rs.24,784mn, Rs.4,649mn
More informationFineotex Chemical Ltd
Company Update Decent Performance under Macroeconomic Pressure; Business Traction to Continue: Fineotex Chemical recorded decent set of result as consolidated sales grew by 1.1% YoY (largely in line) to
More informationSolar Industries India Ltd
RESULT UPDATE 15 th May, 2018 May-15 Nov-15 May-16 Nov-16 May-17 Nov-17 May-18 India Equity Institutional Research II Result Update - Q4FY18 II 15 th May, 2018 CMP INR 1091 Target INR 1353 Potential Upside
More informationBajaj Finserv (BAFINS) 3130
Company Update Rating matrix Rating Buy Target 3470 Target Period 12 months Potential Upside 11% What s Changed? Target Changed from 2900 to 3470 EPS FY17E EPS FY18E EPS FY19E Introducing at 242.3 Rating
More informationBajaj Finserv (BAFINS) 5443
Aug-17 Jun-17 Apr-17 Feb-17 Dec-16 Oct-16 Aug-16 May-16 Mar-16 Jan-16 Nov-15 Sep-15 Company Update Rating matrix Rating Buy Target 6000 Target Period 12 months Potential Upside 10% What s Changed? Target
More informationBajaj Finserv (BAFINS) 4375
Company Update Rating matrix Rating Buy Target 4900 Target Period 12 months Potential Upside 12% What s Changed? Target Changed from 3620 to 4900 EPS FY17E Changed from 146.2 to 150.3 EPS FY18E Changed
More informationD-Link India (DLILIM) 105
Company Update Rating matrix Rating : Buy Target : 140 Target Period : 18-24 months Potential Upside : 34% What s Changed? Target Changed from 150 to 140 EPS FY18E Changed from 11.4 to 9.5 EPS FY19E Introduced
More informationSchaeffler India (FAGBEA) 4800
Event update Rating Matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Stock Data Particular Amount Market Capitalization ( crore) 7,968 Net Debt (CY16) ( crore) (640.6) Net Worth
More informationWabco India (WABTVS) Having a safe and brake free ride! Management Meet Note. ICICI Securities Ltd Retail Equity Research.
Management Meet Note Rating matrix Rating : Buy Target : 6750 Target Period : 12 months Potential Upside : 14% What s Changed? Target Changed from 6400 to 6750 EPS FY17E Unchanged EPS FY18E Unchanged Rating
More informationHCC BUY. Infrastructure April 10, QIP step in the right direction EVENT UPDATE. India Research. Bloomberg: HCC IN Reuters: HCNS.
Jan-14 Mar-14 Apr-14 May-14 Jul-14 Aug-14 Sep-14 Nov-14 Dec-14 Jan-15 India Research Infrastructure April 10, 2015 EVENT UPDATE Bloomberg: IN Reuters: HCNS.BO BUY QIP step in the right direction has successfully
More informationReliance Capital (RELCAP) 549
Company Update Rating matrix Rating Buy Target 718 Target Period 12 months Potential Upside 31% Key Financials crore FY16E FY17E FY18E FY19E Revenues 9998 16776 18727 21501 PBT 1733 1459 1974 2560 Adjusted
More informationAhluwalia Contracts (India)
May-14 Jul-14 Aug-14 Sep-14 Oct-14 Dec-14 Jan-15 Feb-15 Apr-15 May-15 India Research Infrastructure May 22, 215 QUARTERLY REVIEW Bloomberg: AHLU IN Reuters: AHLU.BO BUY Better performance ahead ACIL posted
More informationReliance Capital (RELCAP)
Event Update Rating matrix Rating : Buy Target : 466 Target Period : 12 months Potential Upside : 41% Key Financials (Consolidated) crore FY10 FY11 FY12E FY13E Revenues 6141 5499 6452 7129 PBT 592 287.3
More informationBUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights
JK 20 NOV 2017 Quarterly Update BUY Target Price: Rs 1,220 White cement steals the show JK Cement s (JKCE) Q2FY18 EBITDA at Rs 2.1 bn (up 30% YoY) was higher than our and consensus estimates, mainly due
More informationMinda Industries Ltd RESULT UPDATE
RESULT UPDATE 22 nd May 2017 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 India Equity Institutional Research II Result Update - Q4FY17 II 22 nd May, 2017 CMP INR 568 Target INR 678 Potential Upside
More informationI Direct. nstinct. September 19, 2017
I Direct nstinct September 19, 2017 I-direct Instinct Key risks to investing in I-direct Instinct It is a quick pitch note, which captures the essence of an idea in brief Instinct idea may be based on
More informationIndusInd Bank (INDBA) 1717
Event Update Rating matrix Rating : Buy Target : 1920 Target Period : 12 months Potential Upside : 12% What s Changed? Target EPS FY18E EPS FY19E Rating Price chart October 16, 2017 IndusInd Bank (INDBA)
More informationI Direct. nstinct. February 7, 2018
I Direct nstinct February 7, 2018 I-direct Instinct Key risks to investing in I-direct Instinct It is a quick pitch note, which captures the essence of an idea in brief Instinct idea may be based on management
More informationMonte Carlo Fashions (MONCAR) 580
Analyst Meet Note December 13, 217 Rating matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Key Financials ( Crore) FY14 FY15 FY16 FY17 Net Sales 53.1 582.6 621.5 584.1 EBITDA
More informationPraj Industries (PRAIN)
Result Update October 18, 211 Rating matrix Rating : Buy Target : 96 Target Period : 12-15 months Potential Upside : 25% WHAT S CHANGED Praj Industries (PRAIN) 77 Key Financials Crore FY1 FY11 FY12E FY13E
More informationHindustan Unilever (RHS)
Jul-14 Aug-14 Oct-14 Nov-14 Dec-14 Feb-15 Mar-15 Apr-15 Jun-15 Jul-15 India Research FMCG July 22, 2015 QUARTERLY REVIEW Bloomberg: HUVR IN Reuters: HLL.BO SELL Higher A&P drove volume growth HUL s Q1FY16
More informationStock Trader: Budget Beneficiary Stock Larsen & Toubro
Stock Trader: Budget Beneficiary Stock Larsen & Toubro Amit Gupta Raj Deepak Singh Azeem Ahmad amit.gup@icicisecurities.com rajdeepak.singh@icicisecurities.com azeem.ahmad@icicisecurities.com February
More informationSimplex Infrastructures
May-14 Jul-14 Aug-14 Sep-14 Nov-14 Dec-14 Jan-15 Mar-15 Apr-15 May-15 India Research Infrastructure May 27, 2015 QUARTERLY REVIEW Bloomberg: SINF IN Reuters: SINF.BO HOLD Working capital ease to improve
More informationHOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights
AMBUJA S 4 MAY 2017 Quarterly Update HOLD Target Price: Rs 232 Margins to improve from Q2 Q1CY17standalone EBITDA at Rs 4.0 bn was in line withconsensus estimate.volume was up 3% YoY to 6 mnt. Realization
More informationLumax Industries (LUMIND)
Management Meet Note Rating matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Key Financials Crore FY14 FY15 FY16 FY17 Net Sales 1,117 1,143 1,255 1,300 EBITDA 51 59 89 100 Net
More informationStock Trader - Power Grid
Stock Trader - Power Grid Research Analysts: Amit Gupta Raj Deepak Singh Azeem Ahmad amit.gup@icicisecurities.com rajdeepak.singh@icicisecurities.com azeem.ahmad@icicisecurities.com ahmad@icicisec com
More informationPC Jeweller (PCJEW) 417 Stepping up store expansion via small store s. Management Meet Note. ICICI Securities Ltd Retail Equity Research
Management Meet Note Rating matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Key Financials ( Crore) Net Sales 4,018.4 5,324.8 6,361.3 7,330.2 EBITDA 481.8 587.7 730.2 731.5
More informationStock Trader - Focus on Budget: Power Grid
Stock Trader - Focus on Budget: Power Grid Amit Gupta Raj Deepak Singh Azeem Ahmad amit.gup@icicisecurities.com rajdeepak.singh@icicisecurities.com azeem.ahmad@icicisecurities.com December 23, 2014 Important
More informationSinger India (SININ) Focus on tapping small appliances segment. Management Meet Note. ICICI Securities Ltd Retail Equity Research.
Management Meet Note Rating matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Key Financials Crore Revenues 118.9 155.9 196.9 243.4 285. 239.4 EBITDA.6 7.9 6.4 8.6 8.2 8. Net
More informationReliance Housing Finance
Sep-17 Jun-17 Apr-17 Feb-17 Dec-16 Oct-16 Aug-16 Jun-16 Apr-16 Jan-16 Nov-15 Sep-15 Management Meet Rating matrix (Reliance Housing Finance) Rating Listing 115-120 Target Period Potential Upside Key financials
More informationI Direct. nstinct. November 27, 2017
I Direct nstinct November 27, 2017 I-direct Instinct Key risks to investing in I-direct Instinct It is a quick pitch note, which captures the essence of an idea in brief Instinct idea may be based on management
More informationMarico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015
RESULTS REVIEW 4QFY15 29 APR 2015 Marico Kaya INDUSTRY FMCG CMP (as on 28 Apr 2015) Rs 1,635 Target Price Rs 1,823 Nifty 8,240 Sensex 27,226 KEY STOCK DATA Bloomberg MAKA IN No. of Shares (mn) 13 MCap
More informationUltraTech Cement (ULTCEM)
April 20, 2009 Cement Company Update UltraTech Cement (ULTCEM) Current Price Rs 546 Potential upside 15.4% Target Price Rs 630 Time Frame 12-15 months Powered by savings Historically, UltraTech Cement
More informationEmmbi Industries (EMMPOL)
Management Meet Note Rating Matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Key Financials Crore Net Sales 2.2 139.7 157.9 182.6 EBITDA 9.8 12.6 15.3 19.7 Net Profit 3.3 3.2
More informationVakrangee Ltd BUY. Speciality Retail. Company Update. Aug 07, Vakrangee Ltd. Recommendation (Rs.)
Company Update Speciality Retail Addition of Service Offerings will Ramp up the Business PAT increased by 38.3% YoY on strong revenue growth: During Q1FY18, the revenue stood at Rs. 13047 Mn as against
More informationI Direct. nstinct. January 4, 2018
I Direct nstinct January 4, 2018 I-direct Instinct Key risks to investing in I-direct Instinct It is a quick pitch note, which captures the essence of an idea in brief Instinct idea may be based on management
More informationLarsen & Toubro Ltd.
Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Volume No.. III Issue No. 163. Larsen & Toubro Ltd. February 26, 2018 BSE Code: 500510 NSE Code: LT Reuters Code:
More informationPunjab National Bank
Nov-14 Dec-14 Jan-15 Mar-15 Apr-15 May-15 Jul-15 Aug-15 Sep-15 Nov-15 India Research Banking November 09, 2015 QUARTERLY REVIEW Bloomberg: PNB IN Reuters: PNBK.BO SELL Asset quality improves but recovery
More informationCement. Pet coke ban to dent margins in short-term. Sector Update. ICICI Securities Ltd Retail Equity Research. November 20, 2017
Sector Update Sectoral View Cement Positive Rating matrix Companies Rating Target Price Old Revised Old Revised Shree Cement Hold Hold 19700 19000 JK Lakshmi Cement Buy Buy 495 470 Mangalam Cement Buy
More informationBUY. At inflection point NTPC. Target Price: Rs 197. Key highlights. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E.
At inflection point Q2FY18 adjusted PAT grew 12% YoY at Rs 27 bn (vs. our estimate Rs 26 bn) in tandem with 17% YoY rise in regulated equity. Core RoE is still healthy at 20.2% though it contracted ~174
More informationI Direct. nstinct. July 10, 2017
I Direct nstinct July 10, 2017 I-direct Instinct Key risks to investing in I-direct Instinct It is a quick pitch note, which captures the essence of an idea in brief Instinct idea may be based on management
More informationConsumer Discretionary Thematic 6.0 : Buy Page Industries
September 21, 2016 Consumer Discretionary Thematic 6.0 : Buy Page Industries Quant Pick Stock Action Initiation Range Target Stoploss Time Frame Page Industries Buy 14950-15150 17500 13750 3 months Research
More informationEquity Advised Portfolio Service (EAPS) External Circulation Permitted January Monthly Update
Equity Advised Portfolio Service (EAPS) External Circulation Permitted January 2018- Monthly Update Salient Features - EAPS What does the service cover? What is not covered? Process Eligibility Tariff
More informationDCB Bank (DCB) 208. Healthy fundamentals priced in. Company Update. ICICI Securities Ltd Retail Equity Research. June 13, 2017
Company Update Rating matrix Rating : Hold Target : 200 Target Period : 12 months Potential Upside : -4% What s Changed? Target Changed from 165 to 200 EPS FY18E EPS FY19E Rating Key Financials Crore FY16
More informationStock Trader: ONGC. Research Analysts.
Research Analysts Amit Gupta Raj Deepak Singh Azeem Ahmad Stock Trader: ONGC amit.gup@icicisecurities.com rajdeepak.singh@icicisecurities.com azeem.ahmad@icicisecurities.com December 3, 2014 Important
More informationStock Trader - Canara Bank: Focus on Budget
Stock Trader - Canara Bank: Focus on Budget Amit Gupta Raj Deepak Singh Azeem Ahmad amit.gup@icicisecurities.com rajdeepak.singh@icicisecurities.com azeem.ahmad@icicisecurities.com January 20, 2015 Important
More informationHOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance
RAMCO S HOLD Target Price: Rs 503 Deleveraging story playing out Ramco Cements total debt reduced by a massive Rs 5 bn to Rs 22 bn in FY16. The company generated total EBITDA of Rs 11.5 bn in FY16 and
More informationUnion Bank of India (UNIBAN)
Result Update Rating matrix Rating : Hold Target : 22 Target Period : 12 months Potential Upside : 5 % Key Financials crore FY1 NII 4192 6216 714 8312 PPP 3659 435 496 552 PAT 275 282 1915 2439 Valuation
More informationPidilite Industries Ltd
Company Update De-stocking as an initial response to GST implementation caused subdued performance; Brighter long term business prospects ahead The company has recorded sales of Rs. 16693 Mn in as against
More informationColgate-Palmolive (India)
Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue
More informationQuant Picks. Quant Pick
October 3, 2017 Quant Picks Quant Pick Stock Action Range Target Stoploss Frame Vedanta Buy 315-320 358 295 1 month Dabur Buy 305-310 310 356 282 1month Research Analyst Amit Gupta amit.gup@icicisecurities.com
More informationFY17 FY18 FY19E FY20E
13-Aug-15 09-Aug-16 06-Aug-17 03-Aug-18 Result Update STRONG BUY * August 13, 2018 Dalmia Bharat Result Update Top-line growth led by improved realization & volume growth The company posted a revenue of
More informationFY17 FY18 FY19E FY20E
3-Aug-15 3-Oct-15 3-Dec-15 3-Feb-16 3-Apr-16 3-Jun-16 3-Aug-16 3-Oct-16 3-Dec-16 3-Feb-17 3-Apr-17 3-Jun-17 3-Aug-17 3-Oct-17 3-Dec-17 3-Feb-18 3-Apr-18 3-Jun-18 Result Update STRONG BUY * August 6, 218
More informationI Direct. nstinct. March 27, 2018
I Direct nstinct March 27, 2018 I-direct Instinct Key risks to investing in I-direct Instinct It is a quick pitch note, which captures the essence of an idea in brief Instinct idea may be based on management
More informationBUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E
RAMCO S BUY Target Price: Rs 435 Efforts on cost cutting paying off Q2 EBITDA at Rs 2.8 bn (up 30% YoY) was ahead of our estimates due to lower-than-expected costs. Average costs (excluding freight) declined
More informationQuant Pick Buy Axis Bank
September 14, 2017 Quant Pick Buy Axis Bank Quant Pick Stock Action Range Target Stoploss Frame Axis Bank Buy 505-513 592 465 3 months Research Analyst Amit Gupta amit.gup@icicisecurities.com Azeem Ahmad
More informationBHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188
RESULTS REVIEW 1QFY15 13 AUG 2014 BHEL SELL INDUSTRY CAPITAL GOODS CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188 Nifty 7,727 Sensex 25,881 KEY STOCK DATA Bloomberg/Reuters BHEL IN/BHEL.BO No. of Shares
More informationInox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart
4QFY216 Result Update Capital Goods May 11, 216 Inox Wind Performance Highlights Quarterly Data (Consolidated) ( ` cr) 4QFY16 4QFY15 % chg (yoy) 3QFY16 % chg (qoq) Total Income 1,829 93 96.6 941 94.2 EBITDA
More informationVadodara II PPA yet to be signed; TP revised upward to Rs126 on FY19x
Gujarat Industries Power India Equity Research Power February 10, 2017 Result Update Emkay Your success is our success Vadodara II PPA yet to be signed; TP revised upward to Rs126 on FY19x CMP Target Price
More informationBajaj Finance (BAJAF) 5498
Management Meet Note Rating matrix Rating : Unrated Target : NA Target Period : NA Potential Upside : NA Key Financials Crore FY12 FY13 FY14 FY15 NII 1,25 1,717 2,215 2,872 PPP 756 1,53 1,349 1,742 PAT
More informationOctober 4, Quant Pick. Research Analyst
October 4, 2017 Quant Pick M&M Quant Pick Stock Action Range Target Stoploss Frame M&M Buy 1265-1280 1460 1175 3 month Research Analyst Amit Gupta amit.gup@icicisecurities.com Azeem Ahmad azeem.ahmad@icicisecurities.com
More informationCompany Overview. Financial Performance
Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Jan/16 CMP: 32.30 February 11, 2016 Stock Details BSE code 526558 BSE ID JAMEHOT Face value ( ) 10 No of shares (m) 8.0 52 week
More informationAsian Paints. Source: Company Data; PL Research
Premium valuations to sustain, Accumulate October 4, 17 Amnish Aggarwal amnishaggarwal@plindia.com +91 Gaurav Jogani gauravjogani@plindia.com +91 8 Rating Accumulate Price Rs1,1 Target Price Rs1,9 Implied
More informationOil & Gas Thematic. Quant Pick
August 18, 2017 Oil & Gas Thematic Quant Pick Gail and Petronet t LNG Quant Pick Stock Action Range Target Stoploss Frame GAIL Buy 376-382 445 342 3 months Petronet LNG Buy 226-230 230 270 205 3months
More informationBUY. Robust quarter with clear growth visibility DILIP BUILDCON. Target Price: Rs 610. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E
Robust quarter with clear growth visibility Dilip Buildcon s (DBL) Q1FY18 sales grew 60% YoY to Rs 16.6 bn, ahead of our estimate of Rs 12.0 bn and consensus of Rs 13.6 bn. EBITDA was up 47% at Rs 3.0
More informationAmber Enterprises India Ltd
3QFY2019 Result Update Consumer Durable February 16, 2019 Amber Enterprises India Ltd Performance Update (` cr) 3QFY19 3QFY18 % yoy 2QFY19 % qoq Revenue 388.8 338.4 14.9 226.3 71.8 EBITDA 22.1 24.1 (8.2)
More information